In the time of the virus, it is as important as ever to remain calm and practice preventative measures.
At the time of writing, WHO characterized COVID-19 (Coronavirus Disease 2019) as a pandemic and has infected over 120,000 people with over 4,000 casualties. With that said, over 66,000 people with confirmed cases of COVID-19 have recovered. Since SARS-CoV-2 (the virus that causes COVID-19) has spread worldwide with no indication of slowing down, developing a rapid and reliable test to detect the virus has been our focus at Biomeme. Within 2 weeks, lead biologist at Biomeme, Jesse vanWestrienen, developed a coronavirus test that is available now with no minimum order quantity.
What Makes Biomeme’s SARS-CoV-2 Go-Strips Different?
SARS-CoV-2 Go-Strips detect the RNA of severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 (COVID-19), also known as “2019-nCoV” or “Wuhan coronavirus.” Two RNA targets for the novel coronavirus are multiplexed together with Biomeme’s process control assay for RNA extraction and RT-PCR (MS2).
RNA Process Control (RNA extraction and RT-PCR control utilizing MS2 bacteriophage)
Each order contains 10 individually packaged Go-Strips (30 reactions to test 30 samples) and quantified RNA Process Control pellets (quantified MS2). The components are shelf-stable (15-30C).
When used with the full Biomeme qPCR platform, 9 samples can be extracted and tested in less than one hour on our Franklin™ Thermocycler.
Read the full article here.